Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

Published:2011-11-16 Issue:2 Volume:14 Page:215-221
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro-Oncology

Author:

Friday B. B.,Anderson S. K.,Buckner J.,Yu C.,Giannini C.,Geoffroy F.,Schwerkoske J.,Mazurczak M.,Gross H.,Pajon E.,Jaeckle K.,Galanis E.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/14/2/215/6224765/nor198.pdf

Reference35 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

3. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

4. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma;International Journal of Molecular Sciences;2024-08-09

2. CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines;2024-06-30

3. Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients;The American Journal of the Medical Sciences;2024-03

4. The epitranscriptome of high-grade gliomas: a promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses;Journal of Translational Medicine;2023-12-09

5. Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine;Current Oncology;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3